Hikal Ltd (HIKAL) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company has initiated a recovery journey in Q1 FY27, transitioning from the regulatory disruption of the previous year to a focus on execution-led growth.
- A significant achievement was receiving the Ecowadis gold medal rating with a score of 84.1/100, placing Hikal in the top 5% of over 175,000 companies assessed globally for sustainable performance.
- The company is strategically diversifying its business, with a clear shift towards becoming a four-division entity (Pharma, Crop Protection, Animal Health, Personal Care), aiming for Pharma and allied businesses to constitute 70-80% of total revenue in the next 2-3 years.
- Despite significant capital investments over the past four years, the company has successfully reduced its net debt from approximately INR 815 crores in FY24 to INR 685 crores by the end of FY26.
- Management has provided a positive outlook for FY27, expecting a 14-16% growth in revenue and a 25-30% growth in EBITDA, driven primarily by a strong recovery in the pharmaceutical segment.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.